PMID- 38421372
OWN - NLM
STAT- Publisher
LR  - 20240229
IS  - 1747-4094 (Electronic)
IS  - 1747-4094 (Linking)
DP  - 2024 Feb 29
TI  - Pomalidomide combined with dexamethasone for the treatment of relapsed/refractory 
      multiple myeloma: a systematic review and meta-analysis.
LID - 10.1080/17474086.2024.2326219 [doi]
AB  - BACKGROUND: To evaluate the efficacy and safety of pomalidomide in combination 
      treatment of relapsed/refractory multiple myeloma (RRMM). METHODS: Published 
      clinical trials were searched in the Cochrane Library, PubMed, EMBASE to February 
      2023. The literature was screened and evaluated according to the inclusion 
      criteria, and the data were analyzed by a random effect model. Overall response 
      rate (ORR), overall survival (OS), progression-free survival (PFS) and full grade 
      or >/= 3 adverse events (AEs) were the outcomes. RESULTS: This study included 31 
      clinical trials, which included 4776 patients. The pooled ORR of the doublet 
      regimens was 33.3% (95%CI: 27-39%) and the triplet regimens was 66% (95%CI: 
      58-74%). Among the 25 included studies, the median PFS was 8.29 months (95%CI: 
      7.27-9.31), and nine studies reported median OS of 19.43 months (95%CI: 
      14.56-24.30). In terms of safety, the most common hematologic AEs of grade >/= 3 
      were neutropenia (41%) and anemia (20%); Non-hematologic AEs were pneumonia (14%) 
      and infection/febrile neutropenia (14%). CONCLUSIONS: Pomalidomide combined 
      treatment regimens have shown good clinical efficacy, especially in 
      pomalidomide + dexamethasone combined with other drugs. In terms of safety, it's 
      important to pay attention to the likelihood of hematological adverse events when 
      used clinically.
FAU - Luo, Ying
AU  - Luo Y
AD  - Key Laboratory of Molecular Target & Clinical Pharmacology and the State Key 
      Laboratory of Respiratory Disease, School of Pharmaceutical Sciences & the Fifth 
      Affiliated Hospital, Guangzhou Medical University, Guangzhou, Guangdong, China.
AD  - Phase I Clinical Research Center, Key Laboratory of Biological Targeting 
      Diagnosis, Therapy and Rehabilitation of Guangdong Higher Education Institutes, 
      The Fifth Affiliated Hospital of Guangzhou Medical University, Guangdong, China.
FAU - Li, Chen
AU  - Li C
AD  - Phase I Clinical Research Center, Key Laboratory of Biological Targeting 
      Diagnosis, Therapy and Rehabilitation of Guangdong Higher Education Institutes, 
      The Fifth Affiliated Hospital of Guangzhou Medical University, Guangdong, China.
FAU - Niu, Yuanchen
AU  - Niu Y
AD  - Key Laboratory of Molecular Target & Clinical Pharmacology and the State Key 
      Laboratory of Respiratory Disease, School of Pharmaceutical Sciences & the Fifth 
      Affiliated Hospital, Guangzhou Medical University, Guangzhou, Guangdong, China.
AD  - Phase I Clinical Research Center, Key Laboratory of Biological Targeting 
      Diagnosis, Therapy and Rehabilitation of Guangdong Higher Education Institutes, 
      The Fifth Affiliated Hospital of Guangzhou Medical University, Guangdong, China.
FAU - Wu, Shuanzhi
AU  - Wu S
AD  - Key Laboratory of Molecular Target & Clinical Pharmacology and the State Key 
      Laboratory of Respiratory Disease, School of Pharmaceutical Sciences & the Fifth 
      Affiliated Hospital, Guangzhou Medical University, Guangzhou, Guangdong, China.
AD  - Phase I Clinical Research Center, Key Laboratory of Biological Targeting 
      Diagnosis, Therapy and Rehabilitation of Guangdong Higher Education Institutes, 
      The Fifth Affiliated Hospital of Guangzhou Medical University, Guangdong, China.
FAU - Tian, Jingyuan
AU  - Tian J
AD  - Key Laboratory of Molecular Target & Clinical Pharmacology and the State Key 
      Laboratory of Respiratory Disease, School of Pharmaceutical Sciences & the Fifth 
      Affiliated Hospital, Guangzhou Medical University, Guangzhou, Guangdong, China.
AD  - Phase I Clinical Research Center, Key Laboratory of Biological Targeting 
      Diagnosis, Therapy and Rehabilitation of Guangdong Higher Education Institutes, 
      The Fifth Affiliated Hospital of Guangzhou Medical University, Guangdong, China.
FAU - Hu, Zhiqin
AU  - Hu Z
AD  - Phase I Clinical Research Center, Key Laboratory of Biological Targeting 
      Diagnosis, Therapy and Rehabilitation of Guangdong Higher Education Institutes, 
      The Fifth Affiliated Hospital of Guangzhou Medical University, Guangdong, China.
FAU - He, Jin
AU  - He J
AD  - Phase I Clinical Research Center, Key Laboratory of Biological Targeting 
      Diagnosis, Therapy and Rehabilitation of Guangdong Higher Education Institutes, 
      The Fifth Affiliated Hospital of Guangzhou Medical University, Guangdong, China.
FAU - Zhang, Zhixin
AU  - Zhang Z
AD  - Phase I Clinical Research Center, Key Laboratory of Biological Targeting 
      Diagnosis, Therapy and Rehabilitation of Guangdong Higher Education Institutes, 
      The Fifth Affiliated Hospital of Guangzhou Medical University, Guangdong, China.
FAU - Liu, Haiyan
AU  - Liu H
AD  - Phase I Clinical Research Center, Key Laboratory of Biological Targeting 
      Diagnosis, Therapy and Rehabilitation of Guangdong Higher Education Institutes, 
      The Fifth Affiliated Hospital of Guangzhou Medical University, Guangdong, China.
FAU - Li, Yongmei
AU  - Li Y
AD  - Phase I Clinical Research Center, Key Laboratory of Biological Targeting 
      Diagnosis, Therapy and Rehabilitation of Guangdong Higher Education Institutes, 
      The Fifth Affiliated Hospital of Guangzhou Medical University, Guangdong, China.
FAU - Wang, Tenghua
AU  - Wang T
AD  - Phase I Clinical Research Center, Key Laboratory of Biological Targeting 
      Diagnosis, Therapy and Rehabilitation of Guangdong Higher Education Institutes, 
      The Fifth Affiliated Hospital of Guangzhou Medical University, Guangdong, China.
FAU - Fang, Yi
AU  - Fang Y
AD  - Key Laboratory of Molecular Target & Clinical Pharmacology and the State Key 
      Laboratory of Respiratory Disease, School of Pharmaceutical Sciences & the Fifth 
      Affiliated Hospital, Guangzhou Medical University, Guangzhou, Guangdong, China.
AD  - Phase I Clinical Research Center, Key Laboratory of Biological Targeting 
      Diagnosis, Therapy and Rehabilitation of Guangdong Higher Education Institutes, 
      The Fifth Affiliated Hospital of Guangzhou Medical University, Guangdong, China.
AD  - Clinical Trial Institution Research Ward, Peking University People's Hospital, 
      Beijing, China.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20240229
PL  - England
TA  - Expert Rev Hematol
JT  - Expert review of hematology
JID - 101485942
SB  - IM
OTO - NOTNLM
OT  - Relapsed/refractory multiple myeloma
OT  - combination regimen
OT  - efficacy
OT  - pomalidomide
OT  - safety
EDAT- 2024/02/29 12:46
MHDA- 2024/02/29 12:46
CRDT- 2024/02/29 10:53
PHST- 2024/02/29 12:46 [medline]
PHST- 2024/02/29 12:46 [pubmed]
PHST- 2024/02/29 10:53 [entrez]
AID - 10.1080/17474086.2024.2326219 [doi]
PST - aheadofprint
SO  - Expert Rev Hematol. 2024 Feb 29. doi: 10.1080/17474086.2024.2326219.